Iam an obg resident with 5.6 height and 76 kgs weight and . I have pimples on my face and pimple scars aswel and pimples most commonly seen at cheek and jawline area and i have blackness at my inner thigh area ,underarms, elbow and i got my periods on 22july so I want to do investigations for this so need a guidance

Reading File
Finding Sources
Finding Sources
Searching PubMed

polycystic ovary syndrome diagnosis investigations hormonal workup

Finding Sources
Finding Sources
Searching PubMed

"polycystic ovary syndrome"[MeSH Terms] AND diagnosis

Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching Images

acanthosis nigricans insulin resistance skin darkening

Clinical photograph of the inguinal-pubic intertriginous region showing obesity-associated acanthosis nigricans with multiple pedunculated skin tags (acrochordons). The image depicts symmetric, hyperpigmented, velvety plaques along skin folds in the groin and inner thighs, with coexisting small, soft, finger-like papillomas along the lesional margins. Skin tone darkening ranges from brown to charcoal-gray, with slight surface gloss and diffuse textural thickening. The surrounding skin is relatively unremarkable aside from mild creasing. Imaging modality: dermatologic clinical photography; technique: close-up, high-resolution color image with diffuse, even illumination to enhance contrast between pigmented, velvety epidermis and normal skin. Anatomical location: intertriginous groin region, including pubic creases and proximal thigh folds; laterality: bilateral; plane: frontal view. Pathophysiology: insulin resistance-driven keratinocyte and epidermal proliferation leading to thickened, hyperpigmented plaques; secondary acrochordons arise in skin folds. Notable features: acanthosis nigricans associated with obesity, metabolic syndrome, and diabetes risk; skin tags reflect friable, pedunculated papillomas. Diagnostic significance: strong indicator of impaired glucose tolerance; warrants metabolic workup (fasting glucose, HbA1c), obesity management, and surveillance for diabetes. Differential considerations include malignant acanthosis nigricans (paraneoplastic) and drug-induced variants. Clinical correlation: correlate BMI, family history, and endocrinologic evaluation; reinforce lifestyle modification. Useful for dermatology education and clinical teaching resources. Appropriate documentation supports patient counseling and referral.

Clinical photograph of the inguinal-pubic intertriginous region showing obesity-associated acanthosis nigricans with multiple pedunculated skin tags (acrochordons). The image depicts symmetric, hyperpigmented, velvety plaques along skin folds in the groin and inner thighs, with coexisting small, soft, finger-like papillomas along the lesional margins. Skin tone darkening ranges from brown to charcoal-gray, with slight surface gloss and diffuse textural thickening. The surrounding skin is relatively unremarkable aside from mild creasing. Imaging modality: dermatologic clinical photography; technique: close-up, high-resolution color image with diffuse, even illumination to enhance contrast between pigmented, velvety epidermis and normal skin. Anatomical location: intertriginous groin region, including pubic creases and proximal thigh folds; laterality: bilateral; plane: frontal view. Pathophysiology: insulin resistance-driven keratinocyte and epidermal proliferation leading to thickened, hyperpigmented plaques; secondary acrochordons arise in skin folds. Notable features: acanthosis nigricans associated with obesity, metabolic syndrome, and diabetes risk; skin tags reflect friable, pedunculated papillomas. Diagnostic significance: strong indicator of impaired glucose tolerance; warrants metabolic workup (fasting glucose, HbA1c), obesity management, and surveillance for diabetes. Differential considerations include malignant acanthosis nigricans (paraneoplastic) and drug-induced variants. Clinical correlation: correlate BMI, family history, and endocrinologic evaluation; reinforce lifestyle modification. Useful for dermatology education and clinical teaching resources. Appropriate documentation supports patient counseling and referral.

Clinical photograph of the posterior and lateral aspect of a patient's neck demonstrating classic features of acanthosis nigricans. The affected skin shows significant hyperpigmentation and symmetric, velvety thickening (lichenification) with prominent, exaggerated skin folds. The texture appears roughened and 'dirty' in appearance, with the most intense darkening occurring within the deeper cutaneous creases. The boundaries of the lesion are poorly defined, blending gradually into the surrounding normal skin. This dermatological manifestation is a key clinical marker often associated with systemic conditions such as insulin resistance, type 2 diabetes mellitus, and metabolic syndrome, or as part of specific genetic syndromes like Alström syndrome. The image serves as an educational example of metabolic-related skin changes and is essential for clinical recognition and diagnosis in endocrinology and dermatology.

Clinical photograph of the posterior and lateral aspect of a patient's neck demonstrating classic features of acanthosis nigricans. The affected skin shows significant hyperpigmentation and symmetric, velvety thickening (lichenification) with prominent, exaggerated skin folds. The texture appears roughened and 'dirty' in appearance, with the most intense darkening occurring within the deeper cutaneous creases. The boundaries of the lesion are poorly defined, blending gradually into the surrounding normal skin. This dermatological manifestation is a key clinical marker often associated with systemic conditions such as insulin resistance, type 2 diabetes mellitus, and metabolic syndrome, or as part of specific genetic syndromes like Alström syndrome. The image serves as an educational example of metabolic-related skin changes and is essential for clinical recognition and diagnosis in endocrinology and dermatology.

Here is your full clinical guidance:

Clinical Assessment & Investigation Plan

Your Symptom Triad Points Strongly to PCOS + Insulin Resistance

Let me break down what each symptom likely means:
SymptomClinical Significance
Acne on cheeks & jawlineAndrogen-driven acne (hyperandrogenism)
Post-acne scarsInflammatory acne, often hormonal
Dark skin at inner thighs, underarms, elbowsAcanthosis nigricans - hallmark of insulin resistance
Regular/irregular periodsKey to PCOS phenotyping
BMI ~24.9 kg/m² (5'6", 76 kg)High-normal BMI - metabolic risk present
Acanthosis nigricans - hyperpigmented velvety skin in intertriginous areas, a strong marker for insulin resistance
The skin changes you describe are acanthosis nigricans - the velvety, hyperpigmented darkening at skin folds (inner thighs, underarms, elbows). This is a cutaneous marker of insulin resistance/hyperinsulinemia. Combined with jawline/cheek acne (androgen distribution), this is a classic PCOS presentation.

Diagnosis of PCOS: Rotterdam 2023 Criteria (Harrison's 22E)

You need 2 out of 3 criteria:
  1. Irregular menses (<8 cycles/year or cycles >35 days)
  2. Clinical or biochemical hyperandrogenism (elevated total/free testosterone, or Ferriman-Gallwey score ≥4-6)
  3. Polycystic ovarian morphology on ultrasound (≥20 antral follicles OR ovarian volume ≥10 cm³) OR elevated AMH
PCOS is a diagnosis of exclusion - you must rule out thyroid disease, hyperprolactinemia, congenital adrenal hyperplasia, and androgen-secreting tumors first.

Investigations to Order (Timing Matters!)

Best time to draw hormones: Day 2-5 of your cycle. Since your period started July 22, you are currently in the ideal window (Day 7-8 - still acceptable for most tests).

Tier 1 - Essential (Order Now)

TestPurposeNotes
Serum Total TestosteroneBiochemical hyperandrogenismIdeally by LC-MS/MS; many labs use immunoassay
Free Testosterone (calculated or direct)More sensitive than total T in women
Serum AndrostenedioneBetter sensitivity (88.3%) vs testosterone (65.1%) for detecting androgen excess in PCOSTietz Lab Medicine
DHEA-SRules out adrenal source / androgen-secreting tumor
LH and FSHLH:FSH ratio often >2:1 in PCOS (not diagnostic alone, but supportive)
Fasting Serum Insulin + Fasting Blood GlucoseQuantify insulin resistanceDrawn simultaneously for HOMA-IR calculation
HbA1cScreens for prediabetes/diabetes
TSHExclude hypothyroidism (causes anovulation + skin changes)
Serum ProlactinExclude hyperprolactinemia
AMH (Anti-Mullerian Hormone)Elevated in PCOS; supports polycystic ovarian morphologyCut-off >35 pmol/L (5 ng/mL) proposed but not standalone diagnostic

Tier 2 - Metabolic Screening (Important Given Acanthosis Nigricans)

TestPurpose
75g OGTT (2-hour glucose)Recommended in PCOS with insulin resistance signs - acanthosis nigricans makes this mandatory
Fasting Lipid ProfileDyslipidemia common in PCOS; especially check triglycerides and HDL
Liver function tests (ALT/AST)Screen for metabolic dysfunction-associated steatotic liver disease (MDSLD), which Harrison's 22E notes is independently elevated in PCOS

Tier 3 - To Exclude Differentials

TestRules Out
17-OH Progesterone (early morning, fasting)Non-classical Congenital Adrenal Hyperplasia (CAH) - can mimic PCOS
Cortisol (morning serum) ± 24h urine free cortisolCushing's syndrome if you have other features

Imaging

InvestigationWhat to Look For
Pelvic Ultrasound (transvaginal preferred)≥20 antral follicles per ovary OR ovarian volume ≥10 cm³ in at least one ovary (Rotterdam 2023)

Your HOMA-IR Calculation (After Getting Results)

Once you have fasting insulin and fasting glucose:
HOMA-IR = (Fasting Insulin in µU/mL × Fasting Glucose in mmol/L) ÷ 22.5
HOMA-IR >2.5 suggests insulin resistance. Given your acanthosis nigricans, expect this to be elevated.

Priority Order for You

Since your period came on July 22 and today is July 30 (Day 8):
  1. Draw all hormones today or by Day 10 at the latest (Day 2-10 window is acceptable)
  2. Fasting bloods (glucose, insulin, lipids, LFTs, HbA1c) - any morning, fasting 8-12 hours
  3. 75g OGTT - within the next week
  4. Pelvic USG - can be done any time, ideally within the first 10 days of cycle

What to Expect / Next Steps

If PCOS is confirmed:
  • Combined oral contraceptive pills (COCPs) containing anti-androgenic progestins (e.g., cyproterone acetate or drospirenone-containing pills) are first-line for managing acne, regulating cycles, and protecting the endometrium (Harrison's 22E)
  • Metformin should be considered given insulin resistance signs and metabolic risk (especially with acanthosis nigricans)
  • Lifestyle modification - even 5% weight reduction improves ovarian function and androgen levels (Berek & Novak's Gynecology)
  • Topical retinoids/azelaic acid for acne scars; dermatology referral for acanthosis nigricans (responds to insulin sensitization)
  • Screen annually for depression, anxiety, hypertension, dyslipidemia - all independently elevated in PCOS

One Important Note on Acanthosis Nigricans at the Elbow

The inner thighs and axillae are classic sites. The elbow is a less typical site - this could still be acanthosis nigricans (especially in darker skin tones), but also consider post-inflammatory hyperpigmentation or friction-induced darkening. If it has a velvety texture, it is acanthosis nigricans. A dermatologist can confirm.

Sources: Harrison's Principles of Internal Medicine 22E (2025), Berek & Novak's Gynecology, Tietz Textbook of Laboratory Medicine 7th Ed, Andrews' Diseases of the Skin; AMH as PCOS biomarker meta-analysis (Fertil Steril, 2024, PMID 38944177).
Disclaimer: This is educational guidance for a medical professional. Please work with your attending or a consultant endocrinologist/gynecologist for your personal management plan.
This is a shared conversation. Sign in to Orris to start your own chat.